225 related articles for article (PubMed ID: 27185477)
1. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies.
Toulon P; Eloit Y; Smahi M; Sigaud C; Jambou D; Fischer F; Appert-Flory A
Int J Lab Hematol; 2016 Aug; 38(4):389-96. PubMed ID: 27185477
[TBL] [Abstract][Full Text] [Related]
2. Do PT and APTT sensitivities to factors' deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?
Martinuzzo M; Barrera L; Rodriguez M; D'Adamo MA; López MS; Otaso JC
Int J Lab Hematol; 2015 Dec; 37(6):853-60. PubMed ID: 26338156
[TBL] [Abstract][Full Text] [Related]
3. Determination of APTT factor sensitivity--the misguiding guideline.
Lawrie AS; Kitchen S; Efthymiou M; Mackie IJ; Machin SJ
Int J Lab Hematol; 2013 Dec; 35(6):652-7. PubMed ID: 23718922
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
Kitchen S; Woolley A
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
[TBL] [Abstract][Full Text] [Related]
5. Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A.
Scand J Haematol; 1980 Oct; 25(4):308-17. PubMed ID: 6782653
[TBL] [Abstract][Full Text] [Related]
6. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
7. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
Kershaw G
Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
[TBL] [Abstract][Full Text] [Related]
9. Applying a direct aPTT ratio (PlatelinLS/ActinFS) permits to identify rapidly and reliably a bleeding-related factor deficiency or a lupus anticoagulant sequential to an isolated prolongation of aPTT in paediatric pre-operative screening.
Li R; Swaelens C; Vandermijnsbrugge F; Cantinieaux B
Eur J Haematol; 2016 Jun; 96(6):578-85. PubMed ID: 26179977
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
Shetty S; Ghosh K; Mohanty D
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):493-7. PubMed ID: 12851537
[TBL] [Abstract][Full Text] [Related]
11. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system.
Testa S; Morstabilini G; Fattorini A; Galli L; Denti N; D'Angelo A
Haematologica; 2002 Dec; 87(12):1265-73. PubMed ID: 12495900
[TBL] [Abstract][Full Text] [Related]
12. Activated partial thromboplastin time as a screening test of minor or moderate coagulation factor deficiencies for canine plasma: sensitivity of different commercial reagents.
Mischke R
J Vet Diagn Invest; 2000 Sep; 12(5):433-7. PubMed ID: 11021430
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
Lawrie AS; Kitchen S; Purdy G; Mackie IJ; Preston FE; Machin SJ
Clin Lab Haematol; 1998 Jun; 20(3):179-86. PubMed ID: 9681235
[TBL] [Abstract][Full Text] [Related]
14. Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions.
Barna L; Triplett DA
Ric Clin Lab; 1989; 19(4):345-54. PubMed ID: 2517350
[TBL] [Abstract][Full Text] [Related]
15. The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal.
Bowyer A; Smith J; Woolley AM; Kitchen S; Hampton KK; Maclean RM; VAN Veen JJ; Makris M
Int J Lab Hematol; 2011 Apr; 33(2):212-8. PubMed ID: 20880301
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
[TBL] [Abstract][Full Text] [Related]
17. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
Favaloro EJ; Kershaw G; Mohammed S; Lippi G
Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies.
Turi DC; Peerschke EI
Am J Clin Pathol; 1986 Jan; 85(1):43-9. PubMed ID: 3940420
[TBL] [Abstract][Full Text] [Related]
19. An Easy Method to Eliminate the Effect of Lupus Anticoagulants in the Coagulation Factor Assay.
Tang N; Yin S
Clin Lab; 2016 Jul; 62(7):1363-1365. PubMed ID: 28164630
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Sysmex CS5100 coagulation analyzer and comparison to the Stago STA-R analyzer for routine coagulation parameters.
Geens T; Vertessen F; Malfait R; Deiteren K; Maes MB
Int J Lab Hematol; 2015 Jun; 37(3):372-81. PubMed ID: 25233923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
